Certain SGLT2 inhibitors, GLP-1 RAs for T2DM also cut CV risk
(HealthDay)—Certain sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide 1 receptor agonists (GLP-1 RAs) demonstrate significant cardiovascular (CV) benefit and should be used for reducing CV risk ...
Nov 30, 2018
0
0